Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Lyell Immunopharma Inc (LYEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: LYEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.46% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 143.49M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 4 | Beta -0.27 | 52 Weeks Range 7.65 - 38.40 | Updated Date 07/4/2025 |
52 Weeks Range 7.65 - 38.40 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -801085.7% |
Management Effectiveness
Return on Assets (TTM) -24.41% | Return on Equity (TTM) -71.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -108835725 | Price to Sales(TTM) 2207.55 |
Enterprise Value -108835725 | Price to Sales(TTM) 2207.55 | ||
Enterprise Value to Revenue 1938.09 | Enterprise Value to EBITDA 0.25 | Shares Outstanding 14808100 | Shares Floating 9573072 |
Shares Outstanding 14808100 | Shares Floating 9573072 | ||
Percent Insiders 11.77 | Percent Institutions 63.64 |
Upturn AI SWOT
Lyell Immunopharma Inc
Company Overview
History and Background
Lyell Immunopharma, Inc. is a T cell reprogramming company dedicated to the pursuit of curative cell therapies for solid tumors. Founded in 2018, it is focused on addressing the complex challenges in immunotherapy, particularly in solid tumors.
Core Business Areas
- T-Cell Reprogramming: Lyell's core business is the research and development of T-cell reprogramming technologies to enhance the ability of T cells to eliminate solid tumors. This includes addressing T cell exhaustion and creating T cells that are more potent and durable.
- Novel Cancer Therapies: The company is developing a pipeline of novel cancer therapies based on its reprogramming technologies, targeting various solid tumor types.
Leadership and Structure
Lyell Immunopharma is led by a team of experienced scientists and executives in the fields of immunotherapy and oncology. The organizational structure is centered around research and development, with a focus on advancing its T-cell reprogramming platform.
Top Products and Market Share
Key Offerings
- LYL-CEL: A T-cell therapy product candidate engineered to target solid tumors. Currently in clinical trials. Revenue is not yet being generated. Competitors include companies developing similar cell therapies such as CRISPR Therapeutics (CRSP), and Adaptimmune Therapeutics (ADAP).
- LYL-TRA: A second T-cell therapy in early-stage development targeting solid tumors. No current market share or revenue. Competitors include companies developing similar cell therapies such as CRISPR Therapeutics (CRSP), and Adaptimmune Therapeutics (ADAP).
Market Dynamics
Industry Overview
The immunotherapy market, particularly cell therapies for solid tumors, is a rapidly growing field with significant unmet medical need. There is considerable competition and innovation in this space.
Positioning
Lyell Immunopharma is positioned as a leader in T-cell reprogramming for solid tumors, with a proprietary technology platform and a pipeline of novel therapies. They aim to address the limitations of existing immunotherapies in treating solid tumors.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is vast, estimated to be hundreds of billions of dollars annually. Lyell is targeting a subset of this market focused on solid tumors treatable with cell therapies. The TAM depends on the clinical success and regulatory approval of their therapies, which are still in development. Early estimates place the addressable market for these therapies in the billions if successful.
Upturn SWOT Analysis
Strengths
- Proprietary T-cell reprogramming technology
- Experienced leadership team
- Focus on addressing a significant unmet medical need (solid tumors)
- Strong scientific foundation
- Pipeline of novel cancer therapies
Weaknesses
- Early stage of development (clinical trials)
- High R&D expenses
- Dependence on clinical trial outcomes
- No current revenue generation
- Intense competition in the immunotherapy space
Opportunities
- Potential for breakthrough therapies in solid tumors
- Partnerships with larger pharmaceutical companies
- Expansion of the T-cell reprogramming platform
- Advancements in immunotherapy technologies
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy companies
- Intellectual property challenges
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- ADAP
- CRSP
- NK
- CARA
Competitive Landscape
Lyell faces intense competition from other immunotherapy companies. Their success depends on the differentiation and efficacy of their T-cell reprogramming platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the expansion of their research and development programs and the progress of their clinical trials.
Future Projections: Future growth is dependent on the success of their clinical trials and the potential for regulatory approval of their therapies. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing LYL-CEL and LYL-TRA through clinical trials and expanding their T-cell reprogramming platform.
Summary
Lyell Immunopharma is a clinical-stage biotech company with a focus on T-cell reprogramming for solid tumors. It has promising technology and pipeline but faces challenges due to high R&D costs, clinical trial risks, and intense competition. Positive clinical trial results and strategic partnerships are crucial for their success. Currently, they generate no revenue and rely on capital markets for funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lyell Immunopharma Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Company press releases
- Market analyst reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share and TAM figures are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lyell Immunopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-06-17 | President, CEO & Director Dr. Lynn Seely M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 300 | Website https://www.lyell.com |
Full time employees 300 | Website https://www.lyell.com | ||
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.